137 related articles for article (PubMed ID: 26998288)
1. Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase IIα.
Nogi H; Uchida K; Kamio M; Kato K; Toriumi Y; Akiba T; Morikawa T; Suzuki M; Kobayashi T; Takeyama H
Mol Clin Oncol; 2016 Mar; 4(3):383-389. PubMed ID: 26998288
[TBL] [Abstract][Full Text] [Related]
2. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
3. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.
Coon JS; Marcus E; Gupta-Burt S; Seelig S; Jacobson K; Chen S; Renta V; Fronda G; Preisler HD
Clin Cancer Res; 2002 Apr; 8(4):1061-7. PubMed ID: 11948114
[TBL] [Abstract][Full Text] [Related]
4. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM
Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851
[TBL] [Abstract][Full Text] [Related]
5. HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients.
Zhu L; Li YF; Chen WG; He JR; Peng CH; Zhu ZG; Li HW
Chin Med J (Engl); 2008 Oct; 121(20):1965-8. PubMed ID: 19080257
[TBL] [Abstract][Full Text] [Related]
6. c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study.
Fritz P; Cabrera CM; Dippon J; Gerteis A; Simon W; Aulitzky WE; van der Kuip H
Breast Cancer Res; 2005; 7(3):R374-84. PubMed ID: 15987433
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
[TBL] [Abstract][Full Text] [Related]
8. The Pathological Response to Anthracycline is Associated with Topoisomerase IIα Gene Amplification in the HER2 Breast Cancer Subset.
Ishikawa T; Sasaki T; Tanabe M; Narui K; Kida K; Shimada K; Shimizu D; Yamada A; Morita S; Oba MS; Kawachi K; Nozawa A; Ichikawa Y; Takabe K; Endo I
J Surg Sci; 2014 Dec; 2(1):10-12. PubMed ID: 25642443
[TBL] [Abstract][Full Text] [Related]
9. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
10. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
[TBL] [Abstract][Full Text] [Related]
12. Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study.
Chen X; Ye G; Zhang C; Li X; Shen K
Chin J Cancer Res; 2016 Dec; 28(6):561-569. PubMed ID: 28174484
[TBL] [Abstract][Full Text] [Related]
13. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
[TBL] [Abstract][Full Text] [Related]
14. A human epidermal growth factor receptor 2 expression-based approach to neoadjuvant chemotherapy for operable breast cancer.
Ishikawa T; Shimizu D; Sasaki T; Morita S; Tanabe M; Ota I; Kawachi K; Nozawa A; Chishima T; Ichikawa Y; Endo I; Shimada H
Jpn J Clin Oncol; 2010 Jul; 40(7):620-6. PubMed ID: 20299497
[TBL] [Abstract][Full Text] [Related]
15. Prognostic potential of topoisomerase IIα and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy.
Biesaga B; Niemiec J; Ziobro M; Wysocka J; Kruczak A
Breast; 2011 Aug; 20(4):338-50. PubMed ID: 21507646
[TBL] [Abstract][Full Text] [Related]
16. Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer.
Iyikesici MS; Basaran G; Dane F; Ekenel M; Yumuk PF; Cabuk D; Teomete M; Turhal NS
Int J Clin Exp Med; 2014; 7(5):1459-64. PubMed ID: 24995112
[TBL] [Abstract][Full Text] [Related]
17. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
Du Y; Zhou Q; Yin W; Zhou L; Di G; Shen Z; Shao Z; Lu J
Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
[TBL] [Abstract][Full Text] [Related]
18. [Expressions of HER2 and Topo IIα in breast cancer and
its clinical significance].
Shuai P
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Nov; 41(11):1143-1147. PubMed ID: 27932758
[TBL] [Abstract][Full Text] [Related]
19. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ
J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
